Universitätsklinikum Hamburg-Eppendorf (UKE)

Hospital


Location: Hamburg, Germany (DE) DE

ISNI: 0000000121803484

ROR: https://ror.org/01zgy1s35

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies (2022) Haegele M, Mueller KR, Denkert C, Schneeweiss A, Sinn BV, Untch M, Van Mackelenbergh MT, et al. Conference contribution When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study (2022) Hampl M, Jaeger A, Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours (2022) Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, Borchmann P, et al. Conference contribution Factors associated with long-term survival after failure a chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphomas:a role for allogeneic stem cell transplantation? (2022) Derigs P, Bethge W, Holtick U, Von Tresckow B, Ayuk F, Penack O, Vucinic V, et al. Conference contribution Prophylaxis of bacterial Infections and Pneumocystis jirovecii pneumonia in Female Patients with hematological and oncological Diseases: Updated Guideline of the Working Group on Infections (AGIHO) of the German Society for Hematology and Oncology (DGHO) (2022) Classen AY, Henze L, Von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Duran GL, Alakel N, et al. Conference contribution Trial in Progress: eine multizentrische Open-label Phase IB/ II Studie zur Bestimmung der Dosierung und Sicherheit von Asciminib bei padiatrischen Patienten mit chronischer myeloischer Leukamie in der chronischen Phase (ASC4kids) (2022) Metzler M, Escherich G, Reinhardt D, Kapoor S, Hoch M, Descamps L, Bayar MA, et al. Conference contribution Real-world data in children with achondroplasia after licensing of Vosoritide (2022) Palm K, Bechthold-Dalla Pozza S, Gausche R, Hoegler W, Hoyer-Kuhn H, Huebner A, Keller A, et al. Conference contribution Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Patient preferences of German and Swiss melanoma patients with regard to life-threatening side effects in the context of adjuvant immunotherapy - a qualitative GerMelaTox-A substudy (2022) Peters W, Maul LV, Huning S, Hassel JC, Heinzerling L, Loquai C, Gutzmer R, et al. Conference contribution The soluble CD83 molecule accelerates wound closure and improves wound healing quality (2022) Royzman D, Peckert-Maier K, Stich L, Wild A, Ostalecki C, Seyferth S, Eming SA, et al. Conference contribution